deltatrials
Completed NA NCT00820157

Cytoreductive Surgery and Transarterial Chemoembolization (TACE) Versus TACE for Hepatocellular Carcinoma

A Prospective Randomized Trial Comparing Cytoreductive Surgery Followed by Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Multinodular Hepatocellular Carcinoma (MNHCC)

Sponsor: Eastern Hepatobiliary Surgery Hospital

Conditions Hepatocellular Carcinoma
Interventions Cytoreductive Surgery TACE
Updated 5 times since 2017 Last updated: Aug 10, 2013 Started: Nov 30, 2008 Primary completion: Nov 30, 2010 Completion: Dec 31, 2012

Listed as NCT00820157, this NA trial focuses on Hepatocellular Carcinoma and remains completed. Sponsored by Eastern Hepatobiliary Surgery Hospital, it has been updated 5 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  5. Jan 2017 — Jun 2018 [monthly]

    Completed NA

    First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eastern Hepatobiliary Surgery Hospital
Data source: Eastern Hepatobiliary Surgery Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Shanghai, China